Patients with severe secondary mitral regurgitation treated with Abbott Laboratories Inc.'s MitraClip had similar one-year outcomes to patients treated with optimal medical management in the MITRA-FR trial.
MITRA-FR primary investigator Jean-Francois Obadia of the Civil Hospices of Lyon in France presented the one-year results of the MITRA-FR, which is funded by the French Ministry of Health and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?